Information Provided By:
Fly News Breaks for April 21, 2016
SRPT
Apr 21, 2016 | 12:21 EDT
RBC Capital analyst Simos Simeonidis cut his price target for Sarepta Therapeutics to $7.50 saying today's briefing documents posted reiterated the FDA's strong views that eteplirsen has not provided sufficient evidence of its efficacy. The analyst continues to expect a Complete Response Letter for eteplirsen by the May 26 action date. Simeonidis sees a 10%-15% probability of the drug getting approved based on the current data. He keeps a Sector Perform rating on Sarepta.
News For SRPT From the Last 2 Days
There are no results for your query SRPT